Want to stay in touch with the latest updates from Pharmaceutical Business review? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: Pharmaceutical Business review
Is this your feed? Claim it!
This round will also bolster the company’s manufacturing offerings and support additional pipeline therapies.
It was jointly led by OrbiMed, Frazier Life Sciences, ARCH Venture Partners and Revelation Partners.
Current investors Medical Excellence Capital, Axon Ventures, S32, LifeForce Capital and LYFE Capital also participated.
New investors joining the ...
The authorisations cover Gobivaz in both 100mg/ml and 50mg/0.5ml formulations, provided in pre-filled syringes with autoinjector formats and passive needle safety guards, to treat adults with axial spondyloarthritis, psoriatic arthritis (with or without methotrexate).
It can also be used for treating rheumatoid arthritis in combination with methotrexate, and ulcerative...
This is in breach of the Texas Health Care Program Fraud Prevention Act.
The ADHD drugs case centred on the medication Quillivant XR, provided to children on Medicaid.
Paxton stated: “Pfizer and Tris Pharma provided adulterated drugs to children for years and changed test results in order to obtain the benefit of taxpayer-funded Medicaid reimbursement.
“U...
The approval follows positive results from the Phase I/II GO29781 study, which demonstrated that Lunsumio SC has pharmacokinetic non-inferiority to intravenous (IV) administration. No unexpected safety issues were observed.
The SC formulation facilitates outpatient initiation and decreases administration time to around one minute compared to the two-to-four-hour IV inf...
The protection for this patent will last until 2037.
Genprex has also obtained similar patent protection for the gene therapy used with PD-L1 antibodies in Korea, and is advancing additional applications in Canada, China, Brazil, Europe and Israel.
If approved, they will also apply to the Phase I/II Acclaim-3 clinical trial.
Acclaim-3 is assessing the com...
